Direct injection of a low dose of the immune checkpoint inhibitor nivolumab into precancerous oral lesions significantly reduced lesion size and risk of cancer progression, sparing most patients from surgery.
To continue reading click here
Low-dose nivolumab injections shrink precancerous oral lesions
